Roivant Sciences targets late September for brepocitinib dermatomyositis launch and 2028 Phase III data for cutaneous sarcoidosis.
Roivant Sciences plans to launch brepocitinib for dermatomyositis by the end of September, marking a key milestone in its pipeline. The company described Q1 2026 as a “calm before the storm” ahead of a busy second half of the year.
Management previously guided for brepocitinib’s commercial debut in 2026 but did not specify a quarter. The drug is also being developed for cutaneous sarcoidosis, with Phase III data expected in 2028. Roivant’s CEO highlighted the upcoming catalysts as pivotal for growth.
Shares showed limited reaction during the earnings call, reflecting investor focus on execution timelines rather than immediate financial results.